Sensei Biotherapeutics Performance dei guadagni passati
Il passato criteri di controllo 0/6
Sensei Biotherapeutics's earnings have been declining at an average annual rate of -12.1%, while the Biotechs industry saw earnings growing at 19% annually.
Informazioni chiave
-12.1%
Tasso di crescita degli utili
103.6%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 17.0% |
| Tasso di crescita dei ricavi | n/a |
| Rendimento del capitale proprio | -56.9% |
| Margine netto | n/a |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Nessun aggiornamento
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16Ripartizione dei ricavi e delle spese
Come Sensei Biotherapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -30 | 14 | 18 |
| 31 Mar 24 | 0 | -32 | 17 | 18 |
| 31 Dec 23 | 0 | -34 | 19 | 18 |
| 30 Sep 23 | 0 | -39 | 20 | 20 |
| 30 Jun 23 | 0 | -45 | 22 | 27 |
| 31 Mar 23 | 0 | -46 | 21 | 28 |
| 31 Dec 22 | 0 | -49 | 20 | 30 |
| 30 Sep 22 | 0 | -46 | 18 | 29 |
| 30 Jun 22 | 0 | -42 | 17 | 26 |
| 31 Mar 22 | 0 | -41 | 16 | 26 |
| 31 Dec 21 | 0 | -37 | 16 | 22 |
| 30 Sep 21 | 0 | -33 | 15 | 18 |
| 30 Jun 21 | 0 | -28 | 13 | 15 |
| 31 Mar 21 | 0 | -23 | 10 | 12 |
| 31 Dec 20 | 0 | -20 | 8 | 11 |
| 30 Sep 20 | 0 | -23 | 6 | 11 |
| 31 Dec 19 | 0 | -21 | 4 | 8 |
Guadagni di qualità: SNSE is currently unprofitable.
Margine di profitto in crescita: SNSE is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: SNSE is unprofitable, and losses have increased over the past 5 years at a rate of 12.1% per year.
Accelerare la crescita: Unable to compare SNSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: SNSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendimento del capitale proprio
ROE elevato: SNSE has a negative Return on Equity (-56.85%), as it is currently unprofitable.